Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

NCT02315612 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

134

Enrollment

NIH

Sponsor class

Conditions

NHL
Large Cell Lymphoma
Follicular Lymphoma
ALL
B-All
B-precursor ALL
Acute Lymphoblastic Leukemia
Acute Lymphocytic Leukemia
B-Non Hodgkin Lymphoma
B-NHL

Interventions

BIOLOGICAL: CD22-CAR

Sponsor

National Cancer Institute (NCI)